What We're Reading: Page 237
Industry reads hand-picked by our editors
Apr 12, 2019
-
The New York Times
The Scary Shortage of Infectious-Disease Doctors
-
LifeSciVC
Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The Middle of Negotiations
-
BioCentury
Regulatory reprieve with Brexit delay
-
Regulatory Focus
EMA Officials Debate Going Beyond Safe and Effective Determinations for New Drugs
Apr 11, 2019
-
STAT
Pharma lobbyists flooded Maryland to block a drug-pricing bill. Opponents pushed back — and won
-
Bloomberg
An AI firm wants to predict costly pharma flops
-
MIT Technology Review
Chinese scientists have put human brain genes in monkeys — and yes, they may be smarter
-
The Japan Times
Nobel laureate Tasuku Honjo says Osaka pharmaceutical firm short-changed him for cancer drug
Apr 10, 2019
Apr 09, 2019
-
The New York Times
The Diagnosis Is Alzheimer’s. But That’s Probably Not the Only Problem.
-
Bloomberg
Drug Middlemen Face State Probes Over 'Complex' Pricing System
-
Slate
When you die, where should we upload your brain?
-
Buzzfeed
Republicans Jim Jordan And Mark Meadows Warn Drug Companies Not To Cooperate With Congressional Investigation
Apr 08, 2019
-
The Wall Street Journal
Botox Rivals Create New Wrinkles for Allergan
-
The New York Times
In a Poor Kenyan Community, Cheap Antibiotics Fuel Deadly Drug-Resistant Infections
-
BioCentury
Big caps under pressure
-
Bloomberg
Gene Therapy Was Hailed as a Revolution. Then Came the Bill.
Apr 05, 2019
Apr 04, 2019
-
Bloomberg
Novartis CEO's $50 Billion of Deals Was Just the First Act
-
The Washington Post
FDA’s Gottlieb heads back to AEI to tackle drug prices
-
Financial Times
Some drug companies are still imposing triple-digit price rises
-
BioCentury
FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market
Previous
